Hearing loss is a common sensory disorder that has been a serious concern globally. It is recently estimated that around 466 million people worldwide have disabling hearing loss, including 34 million children, and this number will increase to over 900 million by 2050 (according to WHO report 2018). The majority of hearing disorders occur due to the death of either inner ear hair cells (HCs) or spiral ganglion neurons (SGNs), thus leading to sensorial neural hearing loss (SNHL). SNHL is known as the most common form of hearing disorder that comprises about 85% of all hearing loss cases. This type of damage is induced by a variety of reasons such as inner ear trauma, ischemia, ototoxic drugs, noise exposure, inflammation, viral infections, genetic deficits, autoimmunologic reaction, and aging. SNHL is generally not reversible due to the lack of regeneration capacity of HCs and SGNs. However, various recent studies have determined that the HCs and SGNs hold a regenerative potential and it is possible to find the cure for SNHL in the near future. This is supported by the clear understanding of the genetical control and signaling pathways involved in the development of HCs and SGNs and their functions, the regenerative potential of residing adult stem cells, and the development of gene therapy and the clinical trials of new pharmaceutical compounds on damaged cochleae. Last year, we have published the first special issue of "Hearing Loss: Reestablish the Neural Plasticity in Regenerated Spiral Ganglion Neurons and Sensory Hair Cells", and this year in this second special issue, we are presenting a new series of articles to report the most recent advances in several major areas as summarized below: HC development, HC damage and protection, HC regeneration, SGN development and protection, inherited hearing loss, and inner ear drug delivery.
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Hair Cell Development

Inner Ear Drug Delivery System
X. Xu et al. ("Hollow Mesoporous Silica@Zeolitic Imidazolate Framework Capsules and Their Applications for Gentamicin Delivery") synthesize a new nanoparticle capsule that can be used as a drug delivery route for the gentamicin transfer at the specific site in the inner ear. The authors also determine the sustained release capacity of gentamicin from the capsule by in vitro and in vivo assays.
We believe that the studies included in this second special issue of "Hearing Loss: Reestablish the Neural Plasticity in Regenerated Spiral Ganglion Neurons and Sensory Hair Cells" provide important insights into cochlear physiology and pathology as well as the important progress in technology that can be translated into clinical application of the medical treatment of cochlear damage in SNHL. We wish that this special issue will represent a significant contribution in the effort to achieve effective protection and treatment of hearing loss in the near future.
